Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

BACKGROUND: This study aimed to evaluate the efficacy, side-effects and resistance mechanisms of first-line afatinib in a real-world setting. METHODS: This is a multicenter observational study of first-line afatinib in Malaysian patients with epidermal growth factor receptor (EGFR)-mutant advanced n...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Ho, Gwo-Fuang, Chai, Chee-Shee, Alip, Adlinda, Wahid, Mohd Ibrahim A., Abdullah, Matin Mellor, Foo, Yoke-Ching, How, Soon-Hin, Zaatar, Adel, Lam, Kai-Seng, Leong, Kin-Wah, Low, John-Seng-Hooi, Yusof, Mastura Md, Lee, Erica Chai-Yong, Toh, Yok-Yong, Liam, Chong-Kin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734518/
https://ncbi.nlm.nih.gov/pubmed/31500587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6107-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia